Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796384 | 0.85 | ADORA3 (0.53) | ADORA3TSHRNFKB1BLMPMP22 | |
| SCHEMBL1796046 | 0.82 | SLC29A1 (0.57) | ADORA3TSHRNFKB1BLMPMP22 | |
| SCHEMBL1797176 | 0.82 | ADORA3 (0.67) | ADORA3TSHRNFKB1BLMPMP22 | |
| SCHEMBL1797623 | 0.81 | SLC29A1 (0.52) | ADORA3ADORA2AADORA1SLC29A1 | |
| SCHEMBL1795810 | 0.81 | ADORA3 (0.52) | ADORA3TSHRNFKB1BLMPMP22 | |
| SCHEMBL1796388 | 0.81 | UBA6 (0.58) | ADORA3TSHRNFKB1BLMPMP22 | |
| SCHEMBL1798260 | 0.81 | SLC29A1 (0.50) | ADORA3ADORA2ASLC29A1 | |
| SCHEMBL1798217 | 0.80 | PRKAG1 (0.51) | ADORA3TSHRNFKB1BLMPMP22 | |
| SCHEMBL1796397 | 0.80 | ADORA3 (0.51) | ADORA3ADORA2AADORA1SLC29A1 | |
| SCHEMBL1796347 | 0.80 | ADORA3 (0.55) | ADORA3TSHRNFKB1BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | ADORA3 3584/4885TSHR 4091/4885NFKB1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.